SITC Cancer Immunotherapy Guideline News

Back to SITC Cancer Immunotherapy Guidelines

Open Comment Period for SITC’s Melanoma Guideline Closes March 16

posted 02-23-2023
The Society for Immunotherapy of Cancer (SITC) Melanoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical ...
0 comments

Open Comment Periods for SITC’s Gynecologic Cancer and Gastrointestinal Cancer Guidelines Close January 27

posted 01-12-2023
The Society for Immunotherapy of Cancer (SITC) is pleased to invite public comment on two new draft clinical practice guidelines (CPGs): “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy ...
0 comments

Help SITC Performance Test Our Next Quality Measure – Apply by January 5

posted 12-20-2022
The Society for Immunotherapy of Cancer (SITC) is currently recruiting practices for clinician-level testing of the draft quality measure: Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint ...
0 comments

New Interactive Tools for SITC’s Nonmelanoma Skin Cancer and Lung Cancer & Mesothelioma Guidelines

posted 11-15-2022
New interactive tools have been developed and integrated into the SITC CPG Mobile App for two of SITC’s guidelines that published in 2022. An overview of the guideline content as well as a highlight of the new tools and ...
0 comments

New Guideline Information and Tools Available – Lymphoma, RCC, ICI-rAEs, Urothelial Cancer & Prostate Cancer

posted 11-09-2022
Previously published guidelines have new and updated content available only in the app. Below is an overview of the guidelines for which updates are available. A full description of the event that prompted the update as well ...
0 comments

New SITC Nonmelanoma Skin Cancer CPG Published in JITC

posted 07-28-2022
SITC is pleased to announce the publication of our newest guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer." Clinicians will ...
0 comments

New SITC Lung Cancer and Mesothelioma CPG Published in JITC

posted 05-31-2022
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma . " This ...
0 comments

SITC Cancer Immunotherapy Guidelines Mini Modules

posted 03-16-2022
SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy Guidelines Mini Modules. Designed for practitioners with a desire to learn but with limited ...
0 comments

SITC Cancer Immunotherapy Guidelines Webinars

posted 03-11-2022
SITC’s Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. On-demand ...
0 comments

SITC CPG Mobile App Update – Multiple Myeloma Guideline: D-Kd PLEIADES data and FDA approval

posted 02-01-2022
The SITC Multiple Myeloma Expert Panel has updated the guidelines content and recommendations based on the November 30, 2021 FDA approval of daratumumab in combination with carfilzomib and dexamethasone (D-Kd) for adult patients ...
0 comments

SITC CPG Mobile App Update – Hepatocellular Carcinoma Guideline: New Treatment Algorithm

posted 01-01-2022
The new hepatocellular carcinoma immunotherapy treatment algorithm was derived from the expert panel recommendations in the published SITC clinical practice guideline . This algorithm, available only in the free SITC ...
0 comments

SITC CPG Update – Breast Cancer Guideline: Withdrawn indication for atezolizumab

posted 12-03-2021
On August 27, 2021, the indication for atezolizumab in combination with nab-paclitaxel as treatment for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 was voluntarily withdrawn by the manufacturer. ...
0 comments

SITC Clinical Practice Guideline Mobile App Now Available

posted 09-14-2021
The Society for Immunotherapy of Cancer (SITC) Clinical Practice Guidelines (CPG) Mobile App is the first and only tool of its kind, developed to provide clinicians with an on-the-go and easy-to-navigate reference with interactive ...
0 comments

SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Hepatocellular Carcinoma Published in JITC

posted 09-12-2021
The “ Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma ” was published in JITC September 12, 2021. SITC’s hepatocellular carcinoma ...
0 comments

SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Breast Cancer Published in JITC

posted 08-13-2021
The “ Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer ” was published in JITC August 13, 2021. SITC’s breast cancer expert panel developed this ...
0 comments

SITC Clinical Practice Guideline on Immunotherapy for the Treatment of Urothelial Cancer Published in JITC

posted 07-15-2021
The “ Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer ” was published in JITC July 15, 2021 as an update to SITC’s 2017 guidelines on bladder ...
0 comments

SITC Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events Published in JITC

posted 06-25-2021
The “ Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events ” was published in JITC June 25, 2021. While ICIs ...
0 comments